Shire, Microsoft and EURORDIS form Global Commission

Pharmaceutical Investing

Shire (NASDAQ:SHPG), Microsoft (NASDAQ:MSFT) and EURORDIS-Rare Diseases Europe today announced a strategic alliance to address the diagnostic challenge for patients living with a rare disease. The long road to diagnosis is one of the most important issues affecting the health, longevity and well-being for rare disease patients and their families. As quoted in the press …

Shire (NASDAQ:SHPG), Microsoft (NASDAQ:MSFT) and EURORDIS-Rare Diseases Europe today announced a strategic alliance to address the diagnostic challenge for patients living with a rare disease. The long road to diagnosis is one of the most important issues affecting the health, longevity and well-being for rare disease patients and their families.

As quoted in the press release:

“We have an opportunity to harness the power of technology to tackle this painful issue that has affected so many. We’re seeking innovative ways to integrate emerging technologies into our efforts, which will play a critical role as we strive to impact the diagnosis journey,” said Kos. “Microsoft is committed to this mission and I believe the Global Commission’s wide range of expertise, along with the infusion of technology, will change the state of rare disease diagnosis.”

Click here to read the full press release.

The Conversation (0)
Ă—